Xiidra (lifitegrast) / Bausch Health - LARVOL DELTA

NGL-Long Term: A Study to Assess the Long-Term Safety of Lifitegrast/Perfluorohexyloctane Fixed-Dose Combination in Subjects With Dry Eye Disease (clinicaltrials.gov) - P3 | N=0 | Withdrawn | Sponsor: Bausch & Lomb Incorporated | N=150 ➔ 0 | Not yet recruiting ➔ Withdrawn

Enrollment change • Trial withdrawal • Dry Eye Disease • Ophthalmology

Switching From Xiidra to TRYPTYR (clinicaltrials.gov) - P4 | N=100 | Not yet recruiting | Sponsor: Southern College of Optometry

New P4 trial • Dry Eye Disease • Ophthalmology

Targeted Therapies and Pharmacologic Advances in Mucous Membrane Pemphigoid: A Comprehensive Review. (PubMed, Dermatol Pract Concept) - "Considering the severity of the condition, progressive fibrosis, and resistance to therapy, more research is required in relation to the pathogenesis of MMP and the efficacy and safety profile of novel pharmacological options. Pharmacological agents should provide the achievement and maintenance of remission with minimal adverse effects. A broader spectrum of pharmacological agents will allow a personalized approach and more alternatives, in particular for recalcitrant cases, failure of the previous therapy, and in patients with MMP and malignancy."

Journal • Review • Dermatology • Fibrosis • Immunology • Infectious Disease • Oncology

Updates in the local treatments in Primary Sjögren's Syndrome "Efficacy and Safety" (ACR Convergence 2025) - "Novel agents such as lifitegrast, diquafosol, and lacritin reported favourable results with minimal adverse effects. In the management of xerostomia, pilocarpine and cevimeline improved salivary output (pilocarpine concentrations significantly increased whole salivary flow compared to placebo (p < 0.01)) and symptom perception (but were limited by systemic adverse effects... Local therapies remain a cornerstone in the management of sicca symptoms in pSS, particularly given the limited access to systemic immunomodulatory drugs. While several interventions demonstrated promising efficacy and safety profiles, most evidence was derived from small, heterogeneous studies. Further research is needed to establish standardised outcome measures, clarify long-term benefits, and guide personalised therapeutic strategies."

Clinical • Dental Disorders • Immunology • Sjogren's Syndrome • Xerostomia • LACRT

Lifitegrast Degradation: Products and Pathways. (PubMed, Pharmaceutics) - "The second and third weak spots are elucidated through bond dissociation energy (BDE) calculations which highlighted the oxidative vulnerabilities of both the piperidine and benzofuran ring. Additionally, two degradation products, observed in initial, extended, and targeted oxidative forced degradation studies, were selected for in silico toxicity assessment and were predicted to have toxicity profiles comparable to or lower than lifitegrast."

Journal • Dry Eye Disease • Ophthalmology

Integrating plasma proteomics and genome-wide association data to identify therapeutic targets for retinal neurodegenerative diseases in Europeans. (PubMed, Int J Ophthalmol) - "This study identified six potential protein targets for RND and five existing drugs with therapeutic potential. By integrating plasma proteomics with genetic data, it provides a cost-effective framework for drug discovery."

Journal • Age-related Macular Degeneration • CNS Disorders • Diabetic Retinopathy • Glaucoma • Macular Degeneration • Ophthalmology • Retinal Disorders • BRD2 • ICAM1 • SVEP1

Comparison of Dry Eye Treatment Outcomes in Patients with or without Autoimmune Disease. (PubMed, Semin Ophthalmol) - "Cyclosporine and lifitegrast treatment does not seem to significantly improve visual acuity and PEE compared to control. However, the presence of autoimmune disease significantly modulates the efficacy of DED treatment."

Journal • Cataract • Dry Eye Disease • Immunology • Oncology • Ophthalmology • Solid Tumor

Unexpected Poor Response to Lifitegrast in Patients With Idiopathic Canalicular Inflammatory Disease (ICID). (PubMed, Ophthalmic Plast Reconstr Surg) - No abstract available

Journal • Inflammation

Acoltremon (Tryptyr) for dry eye disease. (PubMed, Med Lett Drugs Ther) - No abstract available

Journal • Dry Eye Disease • Ophthalmology

A Clinical Evaluation of Lifitegrast Ophthalmic Solution 5% in Symptomatic Contact Lens Wearers. (PubMed, Clin Ophthalmol) - "Cytokine levels did not change over time. Lifitegrast significantly improved end-of-day dryness, end-of-day discomfort, CLDEQ-8 scores and comfortable CL wear time within 2 weeks of use."

Clinical • Journal • Dry Eye Disease • Ophthalmology

NGL-Long Term: A Study to Assess the Long-Term Safety of Lifitegrast/Perfluorohexyloctane Fixed-Dose Combination in Subjects With Dry Eye Disease (clinicaltrials.gov) - P3 | N=150 | Not yet recruiting | Sponsor: Bausch & Lomb Incorporated

New P3 trial • Dry Eye Disease • Ophthalmology

A Study Evaluating the Safety and Efficacy of a Fixed-Dose Combination for Dry Eye Disease (clinicaltrials.gov) - P2 | N=423 | Not yet recruiting | Sponsor: Bausch & Lomb Incorporated

New P2 trial • Dry Eye Disease • Ophthalmology

A Study to Explore Signs, Symptoms, and Biomarkers in Dry Eye Disease Participants Following Anti-inflammatory Treatment (clinicaltrials.gov) - P4 | N=350 | Recruiting | Sponsor: Hoffmann-La Roche | Not yet recruiting ➔ Recruiting

Biomarker • Enrollment open • Dry Eye Disease • Ocular Inflammation • Ophthalmology

Exposure to Dietary Nitrite Exacerbates Lupus in MRL/lpr Mice by Enhancing Integrin Alpha M. (PubMed, Inflammation) - "To explore this mechanism, the integrin antagonist lifitegrast was used to inhibit the expression of Itgam in the nitrite-exposed MRL/lpr mice, resulting in attenuation of nitrite-induced lupus exacerbation. Collectively, these findings suggested that nitrite exposure could aggravate lupus by promoting Itgam expression."

Journal • Preclinical • Glomerulonephritis • Immunology • Inflammatory Arthritis • Lupus • Lupus Nephritis • Nephrology • Systemic Lupus Erythematosus • ITGAM • TNFA

Topical Pharmacologic Treatments for Dry Eye Disease: A Systematic Review. (PubMed, Ocul Surf) - "Current topical pharmacologic eye products improved signs, and sometimes symptoms, of DED and were well tolerated. Treatment selection should use a shared decision-making approach that takes DED etiology and patient preferences into account."

Journal • Review • Dry Eye Disease • Inflammation • Ocular Inflammation • Ophthalmology

Navigating the Dry Eye Therapeutic Puzzle: A Mechanism-Based Overview of Current Treatments. (PubMed, Pharmaceuticals (Basel)) - "Anti-inflammatory agents including cyclosporine, lifitegrast, and short-term corticosteroids improve ocular surface signs, with mixed symptom relief...Nerve-targeted therapies, including oral neuromodulators (gabapentin, antidepressants), botulinum toxin, and transcutaneous nerve stimulation, have shown potential for managing neuropathic ocular pain, although randomized data are limited... Personalized, mechanism-based treatment strategies are essential for optimizing outcomes in DED. Future research should prioritize well-designed, controlled studies to clarify the role of emerging therapies and guide the individualized management of this heterogeneous condition."

Journal • Review • Dry Eye Disease • Inflammation • Neuralgia • Ocular Inflammation • Ophthalmology • Optic Neuritis • Pain

Recent Advances in Targeted Immunomodulatory Therapies for Chronic Ocular Surface Diseases. (PubMed, Semin Ophthalmol) - "In contrast, targeted immunomodulators such as cyclosporine, tacrolimus, lifitegrast, tofacitinib, and reproxalap provide more selective modulation of the immune response. While corticosteroids are indispensable for acute management, targeted immunomodulatory therapies offer a safer and more sustainable approach for long-term treatment of chronic ocular surface inflammation. The emergence of novel topical agents supports a shift toward precision immunotherapy in ophthalmology."

Journal • Review • Cataract • Conjunctivitis • Dry Eye Disease • Graft versus Host Disease • Immunology • Infectious Disease • Inflammation • Ocular Infections • Ocular Inflammation • Ophthalmology

Real-World Experience with Lifitegrast Ophthalmic Solution in Patients with Dry Eye Disease: A Provider Survey in the USA and Canada. (PubMed, Ophthalmol Ther) - "This real-world survey showed that ECPs use lifitegrast to treat one fifth of their patients with DED and reported moderate-to-high personal and patient satisfaction with lifitegrast treatment."

Journal • Real-world evidence • Cataract • Dry Eye Disease • Ophthalmology • Pain

Lifitegrast Eye Drops in Healthy Subjects：Phase I Study (clinicaltrials.gov) - P1 | N=24 | Completed | Sponsor: Qilu Pharmaceutical Co., Ltd.

New P1 trial • Dry Eye Disease • Ophthalmology

Topical lifitegrast therapy for dry eye disease. (PubMed, Cochrane Database Syst Rev) - "This is a protocol for a Cochrane Review (intervention). The objectives are as follows: To assess the effectiveness and safety of topical lifitegrast therapy alone or in combination with artificial tears, compared with a placebo, artificial tears alone, or no treatment for dry eye disease."

Journal • Dry Eye Disease • Ophthalmology

A Study to Explore Signs, Symptoms, and Biomarkers in Dry Eye Disease Participants Following Anti-inflammatory Treatment (clinicaltrials.gov) - P4 | N=350 | Not yet recruiting | Sponsor: Hoffmann-La Roche

Biomarker • New P4 trial • Dry Eye Disease • Ocular Inflammation • Ophthalmology

Pharmacovigilance Analysis of Lifitegrast-Associated Adverse Events Using the FDA Adverse Event Reporting System (FAERS) Database. (PubMed, Ocul Immunol Inflamm) - "Most lifitegrast-related AEs identified in this study were consistent with those described on the drug label, but some other signals potentially associated with lifitegrast were identified. Prospective studies are needed to verify and clarify these AEs' relationship to lifitegrast."

Adverse events • Journal • Dry Eye Disease • Infectious Disease • Musculoskeletal Diseases • Ophthalmology

Drug-Related Visual Blurring: Findings from the U.S. Food and Drug Administration Adverse Event Reporting System Database. (PubMed, Eur J Pharmacol) - "Preventing drug-related vision issues is vital. Early risk assessment and intervention with personalized medication can reduce side effects, ensure safety, and improve quality of life."

Adverse events • Journal • Oncology • Ophthalmology • Retinal Disorders

Utilising AI for the Identification and Validation of Novel Therapeutic Targets and Repurposed Drugs for Endometriosis (WCE 2025) - "Both subcutaneous and intraperitoneal administration of Lifitegrast, an approved ITGB2 antagonist, effectively suppresses lesion growth...Conclusion The study leveraged an AI target discovery platform to analyze transcriptomic datasets from patients with endometriosis and healthy controls. This innovative approach identified multiple novel targets and drug repurposing opportunities, underscoring AI's potential to accelerate the discovery of novel drug targets and facilitate the repurposing of treatment modalities for endometriosis."

Endometriosis • Gynecology • Women's Health • HCK • ITGB2

A Study of the Drugs AGN-242428 and AGN-231868 in Participants With Dry Eye Disease (clinicaltrials.gov) - P1/2 | N=292 | Completed | Sponsor: AbbVie | Phase classification: P2 ➔ P1/2

Phase classification • Dry Eye Disease • Ophthalmology